Neuropathic Pain Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies – Pfizer, Vistagen, Algiax Pharmaceuticals, and Centrexion Therapeutics

May 04 23:50 2022
Neuropathic Pain Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies - Pfizer, Vistagen, Algiax Pharmaceuticals, and Centrexion Therapeutics
Delveinsight Business Research LLP
DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neuropathic Pain Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Neuropathic Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Neuropathic Pain Market

Neuropathic Pain: An Overview

Neuropathic pain (NP) is now defined by the International Association for the Study of Pain (IASP) as ‘pain caused by a lesion or disease of the somatosensory nervous system.’ This replaces the older definition of ‘pain initiated or caused by a primary lesion, dysfunction or transitory perturbation of the peripheral or central nervous system.

It is caused by a lesion or disease of the somatosensory system, including peripheral fibers (Aβ, Aδ, and C fibers) and central neurons, and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described. Its incidence is likely to increase due to the aging global population, increased incidence of diabetes mellitus, and improved survival from cancer after chemotherapy.

Neuropathic Pain Market Key Facts

  • As per the International Association for the Study of Pain (2014–2015), of the 33 million people affected with HIV across the world, around 35% had neuropathic pain, which did not respond well to standard treatments.

  • As per the article by Bouhassira (2018) titled “Neuropathic pain: Definition, assessment and epidemiology,” epidemiological studies have shown that their prevalence in the general population may be as high as 7–8%, accounting for 20–25% of individuals with chronic pain.

  • As per DelveInsight, men were more affected by neuropathic pain than women.

Neuropathic Pain Market

The Neuropathic Pain market size shall grow during the forecast period owing to the launch of upcoming therapies and increased patient pool in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Neuropathic Pain market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Neuropathic Pain market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Neuropathic Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Neuropathic Pain Epidemiology Segmentation

  • Total Prevalent Cases of Neuropathic Pain

  • Gender-specific Prevalent Cases of Neuropathic Pain

  • Cause-specific Prevalent Cases of Neuropathic Pain

  • Diagnosed and Treatable Cases of Neuropathic Pain

Neuropathic Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuropathic Pain market or expected to get launched during the study period. The analysis covers Neuropathic Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuropathic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Neuropathic Pain Therapeutics Analysis

The Neuropathic Pain Market dynamics is anticipated to change in the coming years due to the rise in healthcare spending across the world and the launch of the emerging therapies.

Some of the key companies in the Neuropathic Pain Market include:

  • Pfizer

  • Vistagen Therapeutics

  • Algiax Pharmaceuticals

  • Centrexion Therapeutics

And many others.

Neuropathic Pain Therapies covered in the report include

  • AV-101 (4-Cl-KYN)

  • ACD440

  • AP-325

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Neuropathic Pain Competitive Intelligence Analysis

4. Neuropathic Pain Market Overview at a Glance

5. Neuropathic Pain Disease Background and Overview

6. Neuropathic Pain Patient Journey

7. Neuropathic Pain Epidemiology and Patient Population

8. Neuropathic Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Neuropathic Pain Unmet Needs

10. Key Endpoints of Neuropathic Pain Treatment

11. Neuropathic Pain Marketed Products

12. Neuropathic Pain Emerging Therapies

13. Neuropathic Pain Seven Major Market Analysis

14. Attribute Analysis

15. Neuropathic Pain Market Outlook (7 major markets)

16. Neuropathic Pain Access and Reimbursement Overview

17. KOL Views on the Neuropathic Pain Market.

18. Neuropathic Pain Market Drivers

19. Neuropathic Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Secondary Myelofibrosis Market

DelveInsight’s “Secondary Myelofibrosis Market” reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the market size and shares analysis in the seven major markets (7MM).

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States